What is Hoth Therapeutics Inc's earnings per share (EPS)?

Hoth Therapeutics Inc (HOTH) reported diluted earnings per share of -$0.90 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Hoth Therapeutics Inc (HOTH) Financials

HOTH

FY2025 annual

Revenue Not reported for FY2025

Net Income -$12.5M -52.3% YoY

EPS (Diluted) -$0.90 YoY not available

Operating Cash Flow -$9.8M -40.5% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 15, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 15, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HOTH SEC filings page.

This page shows Hoth Therapeutics Inc (HOTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HOTH FY2025 2026-08-29

Persistent operating cash consumption is being funded externally while the short-term balance-sheet cushion narrows.

The FY2025 net loss of $12.5M was larger than operating cash flow of -$9.8M, so reported losses did not translate one-for-one into cash use. FY2024 showed the same direction—net loss of $8.2M versus operating cash flow of -$7.0M—making the accounting-to-cash gap a recurring feature rather than a one-period anomaly.

Positive financing cash flow of $9.3M coincided with shares outstanding reaching 15.5M, indicating that ongoing operations were funded partly through financing rather than internally generated cash. That pattern matters because operating cash flow remained negative, so financing was not merely supporting expansion from a cash-generating base.

The current ratio fell from 9.2x to 4.7x, showing that the liquidity cushion narrowed even though short-term resources still exceeded obligations. Reported liquidity equaled 7.6 months of FY2025 operating outflow, a comparison of one balance with one annual outflow rather than a forecast of future operating capacity.

Financial Health Signals

Financial health score not available

Hoth Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Hoth Therapeutics Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Hoth Therapeutics Inc reported a net loss of $12.5M while operations used $9.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$2.7M

YoY+22.5%

Hoth Therapeutics Inc reported -$2.7M in net income in Q1 2026. This represents an increase of 22.5% from the same quarter a year earlier.

EPS (Diluted)

-$0.17

YoY+37.0%

Hoth Therapeutics Inc earned -$0.17 per diluted share (EPS) in Q1 2026. This represents an increase of 37.0% from the same quarter a year earlier.

Revenue

Not reported for Q1 2026.

EBITDA

Not reported for Q1 2026.

Cash & Balance Sheet

Cash & Debt

$4.0M

YoY-64.2%

QoQ-35.2%

5Y CAGR-26.8%

Hoth Therapeutics Inc held $4.0M in cash as of Q1 2026; long-term debt is not reported for that period.

Shares Outstanding

16M

YoY+23.4%

QoQ+4.8%

5Y CAGR-6.5%

Hoth Therapeutics Inc had 16M shares outstanding in Q1 2026. This represents an increase of 23.4% from the same quarter a year earlier. Against the prior quarter it is up 4.8%.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Return on Equity

-64.7%

YoY-34.6pp

Hoth Therapeutics Inc's ROE was -64.7% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is down 34.6 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q1 2026.

Operating Margin

Not reported for Q1 2026.

Net Margin

Not reported for Q1 2026.

Capital Allocation

R&D Spending

$1.5M

YoY-22.4%

Hoth Therapeutics Inc invested $1.5M in research and development in Q1 2026. This represents a decrease of 22.4% from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2026.

Capital Expenditures

Not reported for Q1 2026.

HOTH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HOTH quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18
R&D Expenses	N/A	$5.9M+83.0%	$3.2M-13.1%	$3.7M-24.1%	$4.9M-33.0%	$7.4M+222.4%	$2.3M+12.7%	$2.0M+157.9%	$785K
SG&A Expenses	N/A	$6.4M+29.2%	$5.0M+17.9%	$4.2M-31.3%	$6.1M	N/A	N/A	N/A	N/A
Operating Income	N/A	-$12.4M-50.5%	-$8.2M-3.3%	-$8.0M+28.1%	-$11.1M+21.5%	-$14.1M-93.1%	-$7.3M+5.4%	-$7.7M-209.2%	-$2.5M
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	-$7.3M+5.4%	-$7.7M-209.3%	-$2.5M
Net Income	N/A	-$12.5M-52.3%	-$8.2M-1.0%	-$8.1M+28.7%	-$11.4M+20.6%	-$14.3M-98.9%	-$7.2M+6.6%	-$7.7M-208.7%	-$2.5M
EPS (Basic)	N/A	-$0.90+29.7%	-$1.28+46.2%	-$2.38+74.9%	-$9.50+40.7%	-$16.02	N/A	N/A	N/A
EPS (Diluted)	—	-$0.90	-$1.28	-$2.38	-$9.50+40.7%	-$16.02	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	14M	6M	3M	1M+34.1%	893,226	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
R&D Expenses	$1.5M-22.4%	N/A	$1.6M+64.3%	$1.0M+61.4%	$2.0M+242.6%	N/A	$994K-25.6%	$644K-3.0%
SG&A Expenses	$1.1M-25.6%	N/A	$2.4M+98.2%	$1.2M+7.5%	$1.5M-4.5%	N/A	$1.2M+10.4%	$1.1M+2.2%
Operating Income	-$2.6M+23.8%	N/A	-$4.1M-83.1%	-$2.2M-27.6%	-$3.5M-60.9%	N/A	-$2.2M-2.1%	-$1.7M+0.5%
Net Income	-$2.7M+22.5%	N/A	-$4.1M-84.2%	-$2.2M-28.6%	-$3.5M-61.9%	N/A	-$2.2M-2.4%	-$1.7M+9.8%
EPS (Basic)	-$0.17+37.0%	N/A	-$0.30+6.3%	-$0.17+32.0%	-$0.27+44.9%	N/A	-$0.32+49.2%	-$0.25+56.1%
EPS (Diluted)	-$0.17+37.0%	N/A	-$0.30	-$0.17	-$0.27	N/A	-$0.32	-$0.25
Diluted Shares (Avg)	16M+24.1%	N/A	14M	13M	13M	N/A	7M	7M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.

HOTH Balance Sheet

HOTH quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18
Total Assets	$7.6M-1.4%	$7.7M-24.7%	$10.2M+32.3%	$7.7M-29.5%	$11.0M+109.5%	$5.2M+84.9%	$2.8M+462.8%	$504K
Current Assets	$6.9M-10.2%	$7.6M-24.7%	$10.2M+31.7%	$7.7M-27.1%	$10.6M+121.1%	$4.8M+81.5%	$2.6M+425.3%	$502K
Cash & Equivalents	$6.2M-11.2%	$7.0M-24.3%	$9.3M+44.5%	$6.4M-24.7%	$8.5M+224.7%	$2.6M+55.5%	$1.7M+498.3%	$283K
Short-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.5M+74.2%	$834K+18.3%	$705K-57.0%	$1.6M+48.5%	$1.1M+84.7%	$597K+35.7%	$440K+26.1%	$349K
Current Liabilities	$1.5M+74.8%	$831K+22.5%	$679K-51.1%	$1.4M+59.9%	$868K+178.0%	$312K-29.1%	$440K+26.1%	$349K
Non-Current Liabilities	$0-100.0%	$3K-89.7%	$26K-89.5%	$250K+6.4%	$235K-17.5%	$285K	$0	$0
Total Equity	$6.2M-10.6%	$6.9M-27.9%	$9.5M+56.2%	$6.1M-38.2%	$9.9M+112.7%	$4.6M+93.9%	$2.4M+1446.2%	$155K
Retained Earnings	-$72.9M-20.6%	-$60.4M-15.7%	-$52.2M-18.4%	-$44.1M-4585.6%	$983K+105.1%	-$19.4M-58.9%	-$12.2M-170.8%	-$4.5M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$5.6M-54.7%	$7.6M-1.4%	$9.2M+5.7%	$10.1M-4.4%	$12.4M+35.6%	$7.7M-24.7%	$8.7M-32.2%	$10.6M-17.6%
Current Assets	$4.9M-60.5%	$6.9M-10.2%	$8.9M+2.8%	$10.1M-4.2%	$12.3M+36.2%	$7.6M-24.7%	$8.7M-32.6%	$10.5M-18.0%
Cash & Equivalents	$4.0M-64.2%	$6.2M-11.2%	$7.8M-1.9%	$9.0M-6.6%	$11.3M+49.6%	$7.0M-24.3%	$8.0M-32.4%	$9.7M-16.4%
Total Liabilities	$1.4M+75.7%	$1.5M+74.2%	$1.0M+24.6%	$365K-47.3%	$815K+23.8%	$834K+18.3%	$813K-48.5%	$692K-64.8%
Current Liabilities	$1.4M+75.7%	$1.5M+74.8%	$1.0M+25.0%	$365K-46.4%	$815K+27.4%	$831K+22.5%	$810K-48.7%	$681K-60.3%
Non-Current Liabilities	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$3K-89.7%	$3K	$11K-95.6%
Total Equity	$4.2M-63.9%	$6.2M-10.6%	$8.2M+3.7%	$9.7M-1.4%	$11.5M+36.6%	$6.9M-27.9%	$7.9M-29.9%	$9.9M-9.0%
Retained Earnings	-$75.6M-18.3%	-$72.9M-20.6%	-$70.2M-20.4%	-$66.1M-17.8%	-$63.9M-17.5%	-$60.4M-15.7%	-$58.3M-15.6%	-$56.1M-16.2%

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.

HOTH Cash Flow Statement

HOTH quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18
Operating Cash Flow	-$10.1M	-$9.8M-40.5%	-$7.0M+17.4%	-$8.4M+9.2%	-$9.3M+23.1%	-$12.1M-97.1%	-$6.1M-24.0%	-$4.9M-135.3%	-$2.1M
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	N/A	$1K-14.9%	$1K+0.1%	$1K
Stock-Based Compensation	N/A	$1.2M+47.7%	$804K+271.6%	$216K-65.1%	$621K-53.1%	$1.3M+79.3%	$738K-70.4%	$2.5M+1644.3%	$143K
Investing Cash Flow	N/A	-$300K	N/A	N/A	$1.2M+802.5%	-$165K+91.0%	-$1.8M-105.3%	-$895K	N/A
Financing Cash Flow	$2.9M	$9.3M+96.3%	$4.7M-58.1%	$11.3M+87.5%	$6.0M-66.8%	$18.2M+108.5%	$8.7M+17.1%	$7.5M+545.2%	$1.2M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	-$3.1M-9.4%	-$2.2M-6.0%	-$2.5M-52.5%	-$2.4M-49.1%	-$2.8M-61.7%	-$2.0M+34.0%	-$1.6M+0.1%	-$1.6M-9.8%
Stock-Based Compensation	$0-100.0%	N/A	$1.1M+300.4%	$56K+687.1%	$220K-57.2%	N/A	$283K+48.9%	$7K-27.6%
Investing Cash Flow	$147K	$0	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$701K-90.1%	$550K-48.1%	$1.6M	$66K	$7.1M	$1.1M	$0-100.0%	N/A

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

HOTH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HOTH quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18
Return on Equity	-202.7%-83.7pp	-119.0%-34.0pp	-85.0%+101.3pp	-186.3%-41.4pp	-144.8%+10.1pp	-154.9%+166.6pp	-321.6%+1288.8pp	-1610.4%
Return on Assets	-164.0%-57.8pp	-106.2%-27.0pp	-79.1%+67.7pp	-146.9%-16.6pp	-130.3%+7.0pp	-137.3%+134.4pp	-271.7%+223.6pp	-495.2%
Current Ratio	4.72-4.5x	9.20-5.8x	14.96+9.4x	5.56-6.6x	12.19-3.1x	15.32+9.3x	5.99+4.5x	1.44
Debt-to-Equity	0.24+0.1x	0.120.0x	0.07-0.2x	0.27+0.2x	0.110.0x	0.13-0.1x	0.18-2.1x	2.25

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Return on Equity	-64.7%-34.6pp	N/A	-49.9%-21.8pp	-22.6%-5.3pp	-30.1%-4.7pp	N/A	-28.1%-8.8pp	-17.3%+0.2pp
Return on Assets	-48.1%-20.0pp	N/A	-44.4%-18.9pp	-21.8%-5.6pp	-28.1%-4.6pp	N/A	-25.5%-8.6pp	-16.2%-1.4pp
Current Ratio	3.39-11.7x	4.72-4.5x	8.81-1.9x	27.57+12.2x	15.08+1.0x	9.20-5.8x	10.71+2.6x	15.41+8.0x
Debt-to-Equity	0.34+0.3x	0.24+0.1x	0.120.0x	0.040.0x	0.070.0x	0.120.0x	0.100.0x	0.07-0.1x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Hoth Therapeutics Inc HOTH	FY2025	N/A	-$12.5M	N/A	$26.0M	—
Lisata Therapeutics Inc LSTA	FY2025	$170K	-$16.6M	N/A	$14.8M	—
Q32 BIO INC QTTB	FY2025	$53.7M	$29.8M	55.5%	$381.0M	67/100
Curis CRIS	FY2025	$9.4M	-$7.6M	-80.3%	$3.3M	42/100
Passage Bio, Inc. PASG	FY2025	N/A	-$45.5M	N/A	$15.3M	—

Where Hoth Therapeutics Inc Ranks

Frequently Asked Questions

Is Hoth Therapeutics Inc profitable?

No, Hoth Therapeutics Inc (HOTH) reported a net income of -$12.5M in fiscal year 2025.

What is Hoth Therapeutics Inc's return on equity (ROE)?

Hoth Therapeutics Inc (HOTH) has a return on equity of -202.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Hoth Therapeutics Inc's operating cash flow?

Hoth Therapeutics Inc (HOTH) recorded an outflow of $9.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Hoth Therapeutics Inc's total assets?

Hoth Therapeutics Inc (HOTH) had $7.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Hoth Therapeutics Inc spend on research and development?

Hoth Therapeutics Inc (HOTH) invested $5.9M in research and development during fiscal year 2025.

How many shares does Hoth Therapeutics Inc have outstanding?

Hoth Therapeutics Inc (HOTH) had 16M shares outstanding as of fiscal year 2025.

What is Hoth Therapeutics Inc's current ratio?

Hoth Therapeutics Inc (HOTH) had a current ratio of 4.72 as of fiscal year 2025, which is generally considered healthy.

What is Hoth Therapeutics Inc's debt-to-equity ratio?

Hoth Therapeutics Inc (HOTH) had a debt-to-equity ratio of 0.24 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Hoth Therapeutics Inc's return on assets (ROA)?

Hoth Therapeutics Inc (HOTH) had a return on assets of -164.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Hoth Therapeutics Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Hoth Therapeutics Inc (HOTH) held $6.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.8M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Hoth Therapeutics Inc's Piotroski F-Score?

Hoth Therapeutics Inc (HOTH) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Hoth Therapeutics Inc's earnings high quality?

Hoth Therapeutics Inc (HOTH) reported a net loss of $12.5M while operations used $9.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.